Evaluation of a workplace hemochromatosis screening program

American Journal of Preventive Medicine

Volumn 16, Issue 4, 1999, Pages 303-306

  Stave, Gregg M ^a   Mignogna, Joseph J ^a   Powell, Gwendolyn S ^a   Hunt, Christine M ^b  

^a GLAXOSMITHKLINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; HEALTH PROMOTION; HEMOCHROMATOSIS; HUMAN; IRON BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PREVENTIVE HEALTH SERVICE; SCREENING; TRANSFERRIN BLOOD LEVEL; WORKPLACE;

EID: 0033136475     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(99)00018-5     Document Type: Review

References (21)

1. Edwards C.Q., Griffen L.M., Goldgar D., Drummond C., Skolnick M.H., Kushner J.P. Prevalence of hemochromatosis among 11,0665 presumably healthy blood donors. N Engl J Med. 318:1988;1355-1362.
2. Wiggers P., Dalhoj J., Kiaer H., et al. Screening for haemochromatosis prevalence among Danish blood donors . J Internal Med. 230:1991;265-270.
3. Edwards C.Q., Kushner J.P. Screening for hemochromatosis. N Engl J Med. 328:1993;1616-1620.
4. Burke W., Thomson E., Khoury M.J., et al. AMA Consensus Statement, Hereditary hemochromatosis. J Am Med Assoc. 280:1998;172-178.
5. Buffone G.J., Beck R.J. Cost-effectiveness analysis for evaluation of screening programs hereditary hemochromatosis . Clin Chem. 40:1994;1631-1636.
6. Kushner J.P. Screening for hemochromatosis. Gastroenterology. 109:1995;315-316.
7. Phatak P.D., Guzman G., Woll J.E., Robeson A., Phelps C.E. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 154:1994;769-776.
8. Balan V., Baldus W., Fairbanks V., Michels V., Burritt M., Klee G. Screening for hemochromatosis a cost-effectiveness study based on 12,258 patients . Gastroenterology. 107:1994;453-459.
9. Adams P.C., Gregor J.C., Kertesz A.E., Valberg L.S. Screening blood donors for hereditary hemochromatosis decision analysis model based on a 30-year database . Gastroenterology. 109:1995;177-188.
10. Baer D.M., Simons J.L., Staples R.L., Rumore G.J., Morton C.J. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med. 98:1995;464-468.
11. World Medical Association Declaration of Helsinki - Recommendations guiding physicians in biomedical research involving human subjects . J Am Med Assoc. 277:1997;925-926.
12. Beilby J., Olynyk J., Ching S., et al. Transferrin index an alternative method for calculating the iron saturation of transferrin . Clin Chem. 38:1992;2078-2081.
13. Niederau C., Fisher R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med. 313:1985;1256-1262.
14. Adams P.C., Speechley M., Kertesz A.E. Long-term survival analysis in hereditary hemochromatosis. Gastroenterol. 101:1991;368-372.
15. Crosby W.H. Hemochromatosis The missed diagnosis . Arch Int Med. 146:1986;1209-1210.
16. Kantrowitz W., Doyle J., Semeraro J., Krane R.J. Prostate cancer screening in a large corporation population. JOEM. 37:1995;1193-1198.
17. Abramson N., Cotton S., Eclels R., Baldock J. Voluntary screening program for prostate cancer detection, rate and cost . South Med J. 87:1994;785-788.
18. Kramer B.S., Brown M.L., Prorrok P.C., Potosky A.L., Gohagan J.K. Prostate cancer screening what we know and what we need to know . Ann Intern Med. 119:1993;914-923.
19. Lindfors K.K., Rosenquist C.J. The cost-effectiveness of mammographic screening strategies. JAMA. 274:1995;881-884.
20. Trehu E.G., Cooper J.N. Cost of screening for colorectal cancer results of a community mass screening program and review of the literature . South Med J. 85:1992;248-254.
21. Byers T., Gorsky R. Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer. 70:(5 Suppl):1992;1288-1295.